miR-125b-1 and miR-378a are predictive biomarkers for the efficacy of vaccine treatment against colorectal cancer

Hironori Tanaka, Shoichi Hazama, Michihisa Iida, Ryouichi Tsunedomi, Hiroko Takenouchi, Masao Nakajima, Yukio Tokumitsu, Shinsuke Kanekiyo, Yoshitaro Shindo, Shinobu Tomochika, Yoshihiro Tokuhisa, Kazuhiko Sakamoto, Nobuaki Suzuki, Shigeru Takeda, Shigeru Yamamoto, Shigefumi Yoshino, Tomio Ueno, Yoshihiko Hamamoto, Yusuke Fujita, Hiroaki Tanaka, Ko Tahara, Ryoichi Shimizu, Kiyotaka Okuno, Koji Fujita, Masahiko Kuroda, Yusuке Nakamura and Hiroaki Nagano

Department of Gastroenterological, Breast and Endocrine Surgery, Yamaguchi University Graduate School of Medicine; Division of Electrical, Electronic and Information Engineering, Graduate School of Sciences and Technology for Innovation, Yamaguchi University, Ube; Department of Surgical Oncology, Osaka City University Graduate School of Medicine, Osaka; Department of Surgery, Kure-Kyosai Hospital, Kure; Department of Surgery, Ogori Daiichi General Hospital, Yamaguchi; Department of Surgery, Kinki University Faculty of Medicine, Osaka-Sayama; Department of Molecular Pathology, Tokyo Medical University, Tokyo, Japan; Department of Gastroenterological, Breast and Endocrine Surgery, Yamaguchi University Graduate School of Medicine; Department of Medicine and Surgery, The University of Chicago, Chicago, USA

Key words
Biomarker, colorectal cancer, miR-125b-1, miR-378a, peptide vaccine

Correspondence
Hiroaki Nagano, Department of Gastroenterological, Breast and Endocrine Surgery, Yamaguchi University Graduate School of Medicine, 1-1-1 Minami-Kogushi, Ube city, Yamaguchi 755-8505, Japan. Tel: +81-836-22-2264; Fax: +81-836-22-2263; E-mail: hnagano@yamaguchi-u.ac.jp

Funding Information
Research program of the Project for Development of Innovative Research on Cancer Therapeutics (P-DIRECT), (Grant/Award Number: ‘11039020’) The Japan Agency for Medical Research and Development (AMED), (Grant/ Award Number: ‘15cm0106085h0005’) Leading Advanced Projects for Medical Innovation (LEAP), (Grant/Award Number: ‘16am0001006h0003’)

Received May 10, 2017; Revised August 24, 2017; Accepted August 27, 2017

Cancer Sci 108 (2017) 2229–2238
doi: 10.1111/cas.13390

Colorectal cancer is the third most commonly diagnosed cancer in males and the second most commonly diagnosed cancer in females, with an estimated 1.4 million cases and 693,900 deaths occurring in 2012. In the past decade, chemotherapy and monoclonal antibody treatment have improved the prognosis of patients with mCRC. However, most of these patients die because the cancer develops tolerance to these agents. There is, therefore, a great need for development of additional treatment.

Immunotherapy has been used to treat mCRC and has the potential to eradicate the disease by activating immune responses. Peptide vaccines are one form of cancer vaccine that induces tumor-specific T-cell responses using tumor-associated antigen-derived peptides. Many phase I and II clinical trials using peptide vaccines have been conducted and these vaccines have provided clinical benefits in a small fraction of patients. Currently, immune checkpoint blockade therapies are a very promising cancer immunotherapy. For example, antibodies blocking PD-1 and PD-L1 have shown durable responses in a number of different advanced malignancies. Additionally, several recent studies suggest alternative targeting strategies for indoleamine 2,3-dioxygenase blockade at the level of gene expression. Furthermore, combination immunotherapy with peptide vaccines and immune-checkpoint blockade therapies that are designed to concurrently activate tumor-specific immune responses and inactivate immunosuppression in the tumor microenvironment may lead to the induction of stronger antitumor responses.
We previously reported a phase I and II study in which five epitope peptides were applied to advanced-stage colon cancer patients. However, active immunotherapy using epitope peptides requires preservation of the host immune system. Hence, it is desirable to identify predictive biomarkers for the selection of patients who are likely to respond well, and to effectively induce specific CTL to epitope peptides.

miRNAs are endogenously expressed non-coding RNAs, 18–25 nucleotides in length, which regulate gene expression at the post-transcriptional level. miRNAs play roles as crucial modulators of various biological processes such as proliferation, tumor initiation and development in CRC. However, miRNAs are also critical regulators of immune responses, and their aberrant expression or dysfunction in the immune system has been associated with cancer. For example, p53 modulates the tumor immune response by regulating PD-L1 through miR-34 in non-small-cell lung cancer. In another example, miR-20b, -21 and -130b are upregulated in advanced CRC cancer and inhibit PTEN expression, resulting in PD-L1 overexpression. In addition, some miRNAs have been mentioned as possible biomarkers for immunotherapy.

Cancer tissues consist of cancer cells and surrounding stromal cells, including inflammatory cells, immune competent cells, endothelial cells, and fibroblasts. Stromal cells in the tumor microenvironment play an important role in cancer metastasis. Cancer stroma interacts with cancer tissues through miRNAs, creating a niche for the cancer cells. A study showed that high levels of miR-21 in the stroma predict short disease-free survival in stage II CRC. In a separate study, miR-21 suppression with antisense inhibitors was shown to prevent fibroblast-to-myofibroblast transdifferentiation in response to TGF-β.

The purpose of the present study was to explore miRNAs as novel predictive biomarkers for the efficacy of immunotherapies before their treatment. We previously reported that three miRNAs might be useful biomarkers. As the cellular origin is crucial for determination of miRNAs, in the present study, we used LCM to separate cancer cells and stromal cells for miRNA analysis. Here we demonstrate the results of miRNA microarray analysis and qRT-PCR in CRC cancer and stromal cells. We suggest that miR-125b-1 and miR-378a may serve as novel predictive biomarkers for active immunotherapies.

Materials and Methods

Summary of the phase I study. Detailed protocol of the phase I study was described previously. Briefly, patients were eligible for enrolment when: (i) they had histologically confirmed CRC without indication for surgical resection; (ii) they had histologically confirmed advanced CRC, were naïve for chemotherapy, had adequate functions of critical organs, and had a life expectancy of ≥3 months. Between February 2009 and November 2012, 96 CRC patients were enrolled under the masking of their HLA-A*2402 status. Among these 96 patients, 26 cases were available for miRNA microarray analysis, and 68 primary CRC tissues were available for qRT-PCR analysis.

Sample collection. In the phase I trial, eight primary CRC tissues from 18 patients were obtained by surgery before treatment. Tissues were snap-frozen in liquid nitrogen and stored at −80°C. In the phase II trial, 26 primary CRC tissues were obtained from 96 patients and were stored as frozen tissues; 16 samples were from the HLA-A*2402-matched group and 10 samples were from the HLA-A*2402-unmatched group. Sixty-eight primary CRC tissues were obtained and stored as FFPE tissues; 34 samples from each of the HLA-A*2402-matched and HLA-A*2402-unmatched groups. Primary CRC lesions were resected in advance of the vaccine treatment studies at Yamaguchi University Hospital and affiliated hospitals. Written informed consent was obtained from all patients. This study was approved by the Institutional Ethics Review Boards of Yamaguchi University and was conducted in accordance with the Declaration of Helsinki (H20-102, Clinical Trial Registration: UMIN00001791).

Microarray analysis. Total RNA was extracted from frozen tissue using a mirVana™ miRNA Isolation Kit (Life Technologies, Carlsbad, CA, USA) according to the manufacturer’s protocol. Concentrations and purities of total RNAs were assessed using a spectrophotometer and DNA integrity was verified using an Agilent RNA 6000 Nano Kit (Agilent Technologies, Santa Clara, CA, USA). OD260/OD280 ratios of each sample were between 2.00 and 2.10, which were accepted as adequate for microarray analysis. The miRNA array analysis was carried out with 1-µg samples of total RNA using the miRCURY LNA™ microRNA Array 6th generation (Exiqon, Vedbaek, Denmark) and the GenePix®4000B (Molecular Devices, Sunnyvale, CA, USA). Relative intensity of each hybridization signal was evaluated using the Microarray Data Analysis Tool Ver3.2 (Fügen, Nagoya, Japan).

Laser capture microdissection. FFPE tumor specimens were sectioned into 15-µm-thick slices, and stained with H&E to enable visualization of histology. LCM was carried out using the LMD system LMD6000 (Leica Microsystems, Tokyo, Japan) to microdissect cancer cells and stromal cells from CRC tissues. At least 30 mm² of cancer cells and 45 mm² of stromal cells were collected from each FFPE specimen. Depending on the percentage of cancer cells and stromal cells in the specimen, this generally required from two to four sections.

© 2017 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.
qRT-PCR. Total RNA was extracted from LCM-captured material using a Qiagen miRNeasy FFPE Kit (Qiagen, Tokyo, Japan) according to the manufacturer’s protocol. Concentrations and purities of the total RNAs were assessed as described for microarray analysis using a spectrophotometer. Expression of miRNAs in both cancer cells and stromal cells was verified by qRT-PCR analysis using TaqMan® MicroRNA Assays (Life Technologies). cDNA was synthesized in a 7.5-μL reaction volume from total RNA (10 ng) using the TaqMan® MicroRNA Reverse Transcription Kit (Applied Biosystems, Waltham, MA, USA). Reactions were incubated at 16°C for 30 min and then at 42°C for 30 min, and were inactivated at 85°C for 5 min. Each cDNA was analyzed in duplicate by qRT-PCR using sequence-specific primers for hsa-miR-125b-1 (ID002378), hsa-miR-224 (ID002099), hsa-miR-486 (ID001278), hsa-miR-147b (ID002262), hsa-miR-196b (ID002215), and hsa-miR-224 (ID001314), or RNU6B (ID001093) in an Applied Biosystems 7300 real-time PCR instrument (Life Technologies). miR-378a was previously known as miR-422b, and hsa-miR-422b has the same sequence as miR-378a (ACUGGACUUGGAGUCAGAAGGC). Each individual assay was carried out in a 20-μL reaction volume with 1.33 μL cDNA, 1.0 μL TaqMan MicroRNA Assay, 10 μL TaqMan™ Universal PCR Master Mix II (Applied Biosystems) with No AmpErase UNG and 7.67 μL nuclease-free water (Applied Biosystems). Reactions were incubated for 10 min at 95°C, and then for 55 cycles with denaturation for 15 s at 95°C and annealing/extension for 60 s at 60°C. Data were analyzed using SDS software v1.3.1 (Life Technologies). Threshold and baseline settings were set according to protocol recommendations.

In situ hybridization. ISH was carried out on 5-μm-thick sections of FFPE samples using the RiboMap Kit (Ventana Medical Systems, Tucson, AZ, USA) on the Discovery ULTRA automated ISH instrument (Ventana Medical Systems). Probes were 5’ DIG-labelled ISH LNAs (miRCURY-LNA detection probes; Exiqon). Sequences of probe for miR-125b-1 and miR-378a were 5’-DIG-N/AGCTCCCAAGAGCCTAACCCGT and 5’-DIG-N/CCTTCTGACTCCTAACGTCAG, respectively. Sequence of the scramble probe for a negative control was 5’-DIG-N/GTGTAAACACGCTTATACGCCCA. The ISH steps after the deparaffinization step were carried out based on the standard protocol provided in the manufacturer’s RiboMap application note. Briefly, after treatment with proteinase K, the slides were hybridized with the detection probe for 8 h at 52°C. The digoxigenins were detected with a polyclonal anti-DIG antibody and an alkaline phosphatase-conjugated secondary antibody (Ventana Medical Systems). Signal was detected using the BlueMap NBT/BCIP substrate kit (Ventana Medical Systems). The sections were counterstained with Kernechtrot as a marker stain and covered with a glass coverslip.

Statistical analysis. In microarray analysis, expression signals were calculated by log2 transformation of the normalized data, and differentially expressed miRNAs were detected by using the fold-change value and the Fisher index using Microsoft Excel 2010 according to a previously reported formula. In qRT-PCR, relative quantities of miRNA levels were determined using the 2-ΔΔCT method after normalization with RNU6B as a standard reference. Differences between groups were estimated using the Mann–Whitney U-test. Categorical variables were compared by using the chi-squared and Fisher’s exact tests. The cut-off value was determined by Youden’s index for each ROC analysis. OS was measured in months from the first vaccination to the day of patient death from any cause. Survival curves were analyzed by the Kaplan–Meier method and the log–rank test, and a Cox’s proportional hazards model was used to estimate the hazard ratio (HR) and the 95% CI for the treatment effect in relation to OS and miRNA expression, other biomarkers, and prognostic clinical information. Statistical analyses were done with JMP V11 (SAS Institute Inc.). P < 0.05 was considered statistically significant.

Results

Selection of candidate miRNAs to predict the efficacy of vaccination. We first carried out microarray analysis of the expression profiles of 1425 miRNAs using eight frozen tissues from patients enrolled in a phase I study. We classified the patients into two groups of four patients each, a responder group and a non-responder group. Responders were defined according to the following criteria: (i) having a PFS period of more than 150 days; or (ii) having an OS period longer than 300 days without any additional chemotherapy. Non-responders were defined according to the following criteria: (i) having a PFS period shorter than 90 days; and (ii) having an OS period shorter than 200 days. Subsequently, on the basis of the relative comparison of hybridization signals of individual miRNAs, we selected the top 30 miRNAs showing significant differences in expression levels between the two groups (Table S1). Next, 26 frozen tissues from the phase II study were analyzed using a miRNA microarray. In this analysis, we examined expression levels of the 30 candidate miRNAs and their association with clinical outcome. The expression levels of six miRNAs were significantly associated with prognosis in the HLA-A*2402-matched groups. There was no difference in prognosis in HLA-A*2402-unmatched groups according to the expression levels of these six miRNAs. Therefore, these miRNAs had the potential to be predictive biomarkers for the efficacy of the vaccine treatment. Expression levels of these six miRNAs and survival analysis are shown in Table 1.

Validation of candidate miRNA expression and association of the miRNA expression levels with clinical outcome. We carried out qRT-PCR analysis of the expression of these six miRNAs in 68 FFPE tissues from the phase II study. The FFPE specimens were separated into cancer cells and stromal cells by LCM. miRNA expression levels were examined in these two types of cells, and association of miRNA expression levels with clinical outcome was evaluated. Characteristics of these 68 patients are listed in Table 2. No difference in any characteristic was found between HLA-A*2402-matched and HLA-A*2402-unmatched groups. Expression levels of the six miRNAs and survival analysis of the patients according to low or high expression of these miRNAs are shown in Table 3. Three predictors were negatively associated with OS in the HLA-A*2402-matched group only: miR-125b-1 in cancer cells (P = 0.040), and miR-378a in both cancer cells (P = 0.009) and stromal cells (P < 0.001). In addition, expression of miR-125b-1 (P = 0.089) and miR-486 (P = 0.092) in stromal cells tended to be negatively associated with OS. Overall survival of the HLA-A*2402-matched and -unmatched groups of patients according to high or low expression of miR-125b-1 or miR-378a is shown in the form of Kaplan Meier curves in Figure 1. These data suggest that miR-125b-1 and miR-378a have the potential to be negative predictive biomarkers for the efficacy of the vaccine treatment.

Univariate and multivariate analysis of the association of 125b-1 and miR-378a expression with OS. Results of univariate and multivariate analyses are shown in Table 4. Expression of miR-378a in both cancer cells (HR, 2.853; 95% CI 1.281–
The expression of miR-378a in stromal cells was confirmed to be an independent predictor of OS by multivariate regression analysis (HR, 2.730; 95% CI, 1.027–7.585; P = 0.044).

**miR-125b-1 and miR-378a localization in tumor tissue.** For specific identification of miR-125b-1 and miR-378a expression in tissue sections, we carried out ISH in tissue sections from patients with a poor prognosis. miR-125b-1 was highly expressed in both cancer and stromal cells (Fig. 2a). Within stromal cells, fibroblast-like cells (Fig. 2b) and mononuclear cells (Fig. 2c) showed strong miR-125b-1 signals. A weak miR-378a signal was observed in both cancer and stromal cells (Fig. 2f). Within stromal cells, fibroblast-like cells showed weak miR-378a signals (Fig. 2g). Such weak signals might be a result of the affinity of LNA probes for miR-378a.

**Discussion**

Findings of the present study showed that miR-125b-1 and miR-378a are negative predictive biomarkers for the efficacy of vaccine treatment against colorectal cancer. To our knowledge, this is the first study to systematically investigate miRNA biomarkers for cancer immunotherapy and to focus on separate analysis of cancer cells and stromal cells within cancer tissue. Previous miRNA microarray analysis by our group showed that miR-196b, miR-378a, and miR-486 are possible predictive biomarkers. However, it should be noted that the sample size was small and that the precise origins of these mRNAs are unknown. In the present study, we used qRT-PCR in an increasing number of samples and used LCM to separate the cancer cells and stromal cells. In addition, we carried out ISH for specific identification of the miRNAs.

---

Table 1. Microarray analysis of candidate miRNA expression and phase II study patient survival analysis (log–rank test)

| miR name | Expression in cancer tissue | Cut-off value | HLA-A*2402 | Group | n | P-value |
|----------|-----------------------------|---------------|------------|-------|---|--------|
| 196b-5p  | 689.1 ± 666.5               | 400           | Matched    | Low   | 7 | 0.001  |
|          | 526.5                       |               | High       | 9     |   | 0.366  |
| 147b     | 483.6 ± 185.2               | 500           | Matched    | Low   | 9 | 0.040  |
|          | 460.0                       |               | High       | 7     |   | 0.366  |
| 378a     | 6225.6 ± 2216.9             | 6500          | Matched    | Low   | 9 | 0.066  |
|          | 6336.7                      |               | High       | 7     |   | 0.515  |
| 486-5p   | 345.3 ± 71.0                | 365           | Matched    | Low   | 11| 0.006  |
|          | 339.0                       |               | High       | 5     |   | 0.998  |
| 224-5p   | 343.2 ± 290.8               | 270           | Matched    | Low   | 8 | 0.011  |
|          | 272.2                       |               | High       | 8     |   | 0.657  |
| 125b-1   | 604.0 ± 312.0               | 550           | Matched    | Low   | 11| 0.021  |
|          | 518.0                       |               | High       | 5     |   | 0.092  |

Table 2. Clinical characteristics of patients in the phase II study whose tissues were analyzed for miRNA using qRT-PCR

| Characteristics | HLA-A*2402 matched (n = 34) | HLA-A*2402 unmatched (n = 34) | P-value |
|-----------------|-------------------------------|-------------------------------|---------|
| Sex             |                               |                               | 0.225   |
| Male            | 14                            | 19                            |         |
| Female          | 20                            | 15                            |         |
| Age (years)     |                               |                               | 0.080   |
| Mean            | 68                            | 64                            |         |
| SD              | 8                             | 8                             |         |
| Range           | 47–82                         | 38–77                         |         |
| Unresectable site |                               |                               | 0.073   |
| Liver           | 19                            | 26                            |         |
| Lung            | 11                            | 10                            | 0.793   |
| Dissemination   | 4                             | 3                             | 0.690   |
| Bone            | 0                             | 2                             | 0.151   |
| Lymph node      | 5                             | 8                             | 0.355   |
| Other           | 3                             | 1                             | 0.303   |
| No. involved organs |                               |                               | 0.302   |
| One             | 27                            | 22                            |         |
| Two             | 6                             | 8                             |         |
| Three           | 1                             | 4                             |         |
| Primary tumor site |                               |                               | 0.431   |
| Colon           | 22                            | 25                            |         |
| Rectum          | 12                            | 9                             |         |

HLA, human leukocyte antigen; SD, standard deviation.
in HLA-matched patients. Previous studies have shown that miR-125b plays crucial roles in immune system development and immunological host defense.\(^{34}\) Upregulated expression of miR-125b may enhance type I interferon expression in airway epithelial cells in eosinophilic chronic rhinosinusitis with nasal polyps.\(^{35}\) and promote classical activation of macrophages.\(^{36,37}\) miR-125b-1 was also found to be specifically upregulated in patients with ulcerative colitis,\(^{38}\) and may

### Table 3. qRT-PCR analysis of candidate miRNA expression and phase II study patient survival analysis (log-rank test)

| miR name | Expression in cancer cells | Expression in stromal cells |
|----------|----------------------------|-----------------------------|
|          | Mean | SD    | Median | Cut-off value | HLA-A*2402 | Group | n | P-value | Mean | SD    | Median | Cut-off value | HLA-A*2402 | Group | n | P-value |
| 196b-5p  | 135.079 × 10⁻² | 169.617 × 10⁻² | 63.862 × 10⁻² | 108.588 × 10⁻² | Matched | Low | 24 | 0.652 | 33.801 × 10⁻² | 40.004 × 10⁻² | 18.673 × 10⁻² | 22.450 × 10⁻² | Matched | Low | 22 | 0.311 |
| 147b     | 1.237 × 10⁻² | 1.254 × 10⁻² | 0.834 × 10⁻² | 1.527 × 10⁻² | Matched | Low | 28 | 0.210 | 0.599 × 10⁻² | 0.535 × 10⁻² | 0.424 × 10⁻² | 0.413 × 10⁻² | Matched | Low | 17 | 0.290 |
| 378a     | 61.995 × 10⁻² | 65.306 × 10⁻² | 40.041 × 10⁻² | 27.856 × 10⁻² | Matched | Low | 15 | 0.009 | 43.009 × 10⁻² | 44.441 × 10⁻² | 28.802 × 10⁻² | 43.080 × 10⁻² | Matched | Low | 23 | 0.001 |
| 486-5p   | 5.450 × 10⁻² | 20.571 × 10⁻² | 2.299 × 10⁻² | 2.290 × 10⁻² | Matched | Low | 18 | 0.165 | 7.569 × 10⁻² | 8.741 × 10⁻² | 4.725 × 10⁻² | 4.766 × 10⁻² | Matched | Low | 19 | 0.092 |
| 224-5p   | 101.859 × 10⁻² | 113.0851 × 10⁻² | 61.063 × 10⁻² | 68.359 × 10⁻² | Matched | Low | 20 | 0.172 | 19.249 × 10⁻² | 19.626 × 10⁻² | 13.315 × 10⁻² | 10.984 × 10⁻² | Matched | Low | 16 | 0.525 |
| 125b-1   | 0.786 × 10⁻² | 1.690 × 10⁻² | 0.289 × 10⁻² | 0.498 × 10⁻² | Matched | Low | 27 | 0.040 | 2.311 × 10⁻² | 2.371 × 10⁻² | 1.554 × 10⁻² | 1.690 × 10⁻² | Matched | Low | 23 | 0.429 |

| miR name | Expression in cancer cells | Expression in stromal cells |
|----------|----------------------------|-----------------------------|
|          | Mean | SD    | Median | Cut-off value | HLA-A*2402 | Group | n | P-value | Mean | SD    | Median | Cut-off value | HLA-A*2402 | Group | n | P-value |
| 196b-5p  | 135.079 × 10⁻² | 169.617 × 10⁻² | 63.862 × 10⁻² | 108.588 × 10⁻² | Matched | Low | 24 | 0.652 | 33.801 × 10⁻² | 40.004 × 10⁻² | 18.673 × 10⁻² | 22.450 × 10⁻² | Matched | Low | 22 | 0.311 |
| 147b     | 1.237 × 10⁻² | 1.254 × 10⁻² | 0.834 × 10⁻² | 1.527 × 10⁻² | Matched | Low | 28 | 0.210 | 0.599 × 10⁻² | 0.535 × 10⁻² | 0.424 × 10⁻² | 0.413 × 10⁻² | Matched | Low | 17 | 0.290 |
| 378a     | 61.995 × 10⁻² | 65.306 × 10⁻² | 40.041 × 10⁻² | 27.856 × 10⁻² | Matched | Low | 15 | 0.009 | 43.009 × 10⁻² | 44.441 × 10⁻² | 28.802 × 10⁻² | 43.080 × 10⁻² | Matched | Low | 23 | 0.001 |
| 486-5p   | 5.450 × 10⁻² | 20.571 × 10⁻² | 2.299 × 10⁻² | 2.290 × 10⁻² | Matched | Low | 18 | 0.165 | 7.569 × 10⁻² | 8.741 × 10⁻² | 4.725 × 10⁻² | 4.766 × 10⁻² | Matched | Low | 19 | 0.092 |
| 224-5p   | 101.859 × 10⁻² | 113.0851 × 10⁻² | 61.063 × 10⁻² | 68.359 × 10⁻² | Matched | Low | 20 | 0.172 | 19.249 × 10⁻² | 19.626 × 10⁻² | 13.315 × 10⁻² | 10.984 × 10⁻² | Matched | Low | 16 | 0.525 |
| 125b-1   | 0.786 × 10⁻² | 1.690 × 10⁻² | 0.289 × 10⁻² | 0.498 × 10⁻² | Matched | Low | 27 | 0.040 | 2.311 × 10⁻² | 2.371 × 10⁻² | 1.554 × 10⁻² | 1.690 × 10⁻² | Matched | Low | 23 | 0.429 |

HLA, human leukocyte antigen; miRNA and miR, microRNA; SD, standard deviation.
Fig. 1. Overall survival (OS) according to miRNA expression. OS of the HLA-A*2402-matched (left side) and -unmatched groups (right side) of phase II study patients according to high or low expression of miR-125b-1 or miR-378a. (a) According to miR-125b-1 in cancer cells. (b) According to miR-125b-1 in stromal cells. (c) According to miR-378a in cancer cells. (d) According to miR-378a in stromal cells. Solid line shows high miRNA expression and dashed line shows low miRNA expression. Statistical analysis was carried out using the log-rank test. HLA, human leukocyte antigen; miRNA and miR, microRNA.
increase risk of CRC through nuclear factor kappa B (NF-κB) activation. However, miR-125b negatively regulates TNF-α expression in neonatal monocytes and inhibits proper TNF-α production in response to LPS. Hence, miR-125b might play the role of an immune suppressor by increasing immune exhaustion, and resulting in the inhibition of the antitumor immune system. Expression of miR-125b-1 in cancer cells seems to be more important than that in stromal cells (Fig. 1a,b), although strong signals were also observed in stromal cells (Fig. 2b,c). miR-125b-1 might be produced by cancer cells and/or stromal cells, and cross-talk by miRNAs between cancer cells and stromal cells might ultimately work as an immune suppressor.

Second, our results indicated that high expression levels of miR-378a in both cancer cells and stromal cells were significantly associated with poor prognosis in HLA-matched patients. Previous reports showed that miR-378 was downregulated in CRC and that miR-378a expression might play an important role as a tumor suppressor gene. In contrast, miR-378a was reported to inhibit cytotoxicity of human NK cells and enhance tumor growth and angiogenesis through repression of the expression of two types of tumor suppressors, Sufu and Fus-1. Hence, after the establishment of tumor microenvironments, the function of miR-378a was thought to be as an immune suppressor. Regarding expression of miR-378a, there were some discrepancies in mRNA expression using ISH, miRNA microarray, and qRT-PCR. Expression level of miR-378a was higher than that of miR-125b-1 in miRNA microarray and qRT-PCR analyses. However, the opposite phenomenon was observed in ISH analysis. The miR-378a signal was weak in the cancer cells and stromal cells, and miR-125b-1 was highly expressed in both cell types. This discrepancy might mean that there were some problems with the affinity of the ISH probe for miR-378a.

In multivariate analysis, miR-378a in stromal cells showed the best performance among the three predictors for selection of patients who are likely to respond well to peptide vaccines (Table 4). We additionally considered whether the combination of miR-125b-1 and miR-378a gave a better predictive power. Because the high expression of miR-125b-1 and miR-378a might be negative predictive factors, we classified 68 patients into three groups according to the number of predictive factors (i.e. high expression of miR-125b-1 or miR-378a in cancer or stromal cells). The OS of each group was shown in the form of Kaplan–Meier curves in Figure S1. There was a significant difference between the “0 factor” group and the “2 factors” group. Hence, the combination of miR-125b-1 and miR-378a in cancer cells and stromal cells might have effective prognostic power. The link between miR-125b-1 and miR-378a with immunotherapy is unclear, and it is very important to identify the target genes of these two miRNAs. Hence, we carried out RNA sequencing using 22 cancer tissues from a phase II study (data not shown). We classified the 22 samples into three groups according to the expression of each miRNA by qRT-PCR analysis: the high expression group in both cancer and stromal cells, the low expression group in both cell types, and the group of others. Difference in gene expression between the “high expression group” and the “low expression group” was assessed by log2 ratio and Ingenuity Pathways Analysis (IPA) (Qiagen). Regarding miR-125b-1, receptor activator of NF-κB (RANK) was downregulated in the “high expression group”, RANK, a member of the TNF receptor family, and its ligand RANKL play important roles in the immune system. T cells activated as a result of RANKL expression stimulate dendritic cells, expressing RANK, to enhance their survival and enhance induction of T-cell response. RANK is a target gene of miR-125b-1 by IPA (Qiagen), and miR-125b-1 might work as an immune suppressor regulating RANK. Regarding miR-378a, RNF125 was downregulated in the “high expression group”. RNF125, E3 ubiquitin ligase, is positive regulator of T-cell activation. miR-378a was considered to regulate RNF125 according to IPA and could also be an immune suppressor. Thus, miR-125b-1 and miR-378a might be therapeutic targets.

It must be mentioned that the mean survival time of the “HLA matched-miRNA high” group appeared to be shorter than that of the “HLA unmatched-miRNA high” group (Fig. 1). However, there was no significant difference between their survival curves (Fig. S2). Furthermore, we investigated side-effects in the “HLA matched-miRNA high” group. The incidence of severe AE in each group of miR-378a is shown in Table S2. There was no significant difference in the incidence of AE between the “HLA matched-miRNA high” group and other groups. It is quite unlikely that vaccine treatment led to deleterious effects in “HLA matched-miRNA low” patients.

It is known that the behavior of cancer cells and the development of tumor tissues are modulated by cross-talk through miRNAs between cancer cells and stromal cells such as...
fibroblasts, endothelial cells, pericytes, immune cells, and local and bone marrow-derived stromal stem cells. Although several studies have reported the importance of miRNAs such as miR-21, miR-17-92a and the miR-106b-25 cluster in cancerous stromal cells, the present study is the first to regard the role of miR-125b-1 and miR-378a in colorectal cancer cells and stromal cells for predictive markers of immunotherapy.

In conclusion, miR-125b-1 and miR-378a expression might be considered novel biomarkers to predict the efficacy of immunotherapy in CRC. Although our results are preliminary and the functions of each of the miRNAs in immune responses are still unclear, the applicability of these miRNAs should be confirmed in a future large-scale study as biomarkers to select patients who can expect a better outcome with the vaccine treatment.

Acknowledgments
This study was carried out as a research program of the Project for Development of Innovative Research on Cancer Therapeutics (P-DIRECT; 11039020), The Japan Agency for Medical Research and Development (AMED; 15cm0106085h0005). This study was supported in part by a grant for Leading Advanced Projects for Medical Innovation (LEAP: 16am0001006 h0003) from the Japan Agency for Medical Research and Development. The authors would like to thank Dr Takuya Tsunoda and Dr Koji Yoshida, Laboratory of Molecular Medicine, Human Genome Center, Institute of Medical Science, The University of Tokyo, for their excellent advice and cooperation and for
providing all of the peptides. The authors thank Ms Naoko Okayama for technical support.

**Disclosure Statement**

Yusuke Nakamura is a stockholder and a scientific advisor of OncoTherapy Science, Inc. The other authors declare no potential conflicts of interest for this article.

**Abbreviations**

AE adverse event
CA19-9 carbohydrate antigen 19-9
CEA carcinoembryonic antigen
CI confidence interval
CRC colorectal cancer
CRP C-reactive protein
DIG digoxigenin
FPPE formalin-fixed paraffin-embedded
HLA human leukocyte antigen
HR hazard ratio
ISH in situ hybridization
LCM laser capture microdissection
LNA locked nucleic acid
miCRC metastatic CRC
miRNA microRNA
NLR neutrophil lymphocyte ratio
OS overall survival
PD-1 programmed death-1
PD-L1 PD-ligand 1
PFS progression-free survival
PTEN phosphatase and tensin homolog
qRT-PCR quantitative RT-PCR
RNF125 ring finger protein 125
ROC receiver operating characteristic
TGF-β transforming growth factor beta
TNF tumor necrosis factor

**References**

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin 2015; 65: 87–108.
2. Xiang B, Snook AE, Magee MS, Waldman SA. Colorectal cancer immunotherapy. Discov Med 2013; 15: 301–8.
3. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004; 10: 909–15.
4. Nagorsen D, Thiel E. Clinical and immunologic responses to active specific cancer vaccines in human colorectal cancer.Clin Cancer Res 2006; 12: 3064–9.
5. Tofilasii SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates containing anti-PD-L1 antibody in cancer. N Engl J Med 2012; 366: 2443–54.
6. Le DT, Uram JN, Wang H et al. PD-1 blockade in tumors with mismatch repair deficiency. N Engl J Med 2015; 372: 2509–20.
7. Muller AJ, DuHadaway JB, Donover PS, Sutanto-Ward E, Prendergast GC. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med 2005; 11: 312–9.
8. Hou D-Y, Muller AJ, Sharma MD et al. Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by sterols of 1-methyl-tryptophan correlates with antitumor responses. Cancer Res 2007; 67: 792–801.
9. Ali OA, Lewin SA, Dranoff G, Mooney DJ. Vaccines combined with immune checkpoint antibodies promote cytoxic T-cell activity and tumor eradication. Cancer Immunol Res 2016; 4: 95–100.
10. Lemke C, Salem A, Krieg A, Weiner G. Abstract 1417: combination cancer immunotherapy using checkpoint blockade and intratumoral virus-like particles containing Cpg ODN. Cancer Res 2016; 76: 1417.
11. Hazama S, Nakamura Y, Takenouchi H et al. A phase I study of combination vaccine treatment of five therapeutic epitope-peptides for metastatic colorectal cancer: safety, immunological response, and clinical outcome. J Transl Med 2014a; 12: 63.
12. Hazama S, Nakamura Y, Tanaka H et al. A phase II study of five peptides combination with oxaliplatin-based chemotherapy as a first-line therapy for advanced colorectal cancer (FXV study). J Transl Med 2014b; 12: 108.
13. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281–97.
14. Wang S, Wang Y, Buyasy N et al. A microRNA panel to discriminate carcinomas from high-grade intraepithelial neoplasms in colonoscopy biopsy tissue. Gut 2013; 62: 280–9.
15. Lodish HF, Zhou B, Liu G, Chen C-Z. Micromanagement of the immune system by microRNAs. Nat Rev Immunol 2008; 8: 120–30.
16. Cortez MA, Ivan C, Valdecasas D et al. PDL1 regulation by p53 via miR-34. J Natl Cancer Inst 2016; 108: djv303.
17. Zha J, Chen L, Zou L et al. MiR-20b-21 and -130b inhibit PTEN expression resulting in B7-H1 over-expression in advanced colorectal cancer. Hum Immunol 2014; 75: 348–53.
18. Zhang Q, Di W, Dong Y et al. High serum miR-183 level is associated with poor responsiveness of renal cancer to natural killer cells. Tumour Biol 2015; 36: 9245–9.
19. Galore-Haskell G, Nemlich Y, Greenberg E et al. A novel immune resistance mechanism of melanoma cells controlled by the ADAR1 enzyme. Oncotarget 2015; 6: 28999–19015.
20. Kijima T, Hazama S, Tsunedomi R et al. MicroRNA-6826 and-6875 in plasma are valuable non-invasive biomarkers that predict the efficacy of vaccine treatment against metastatic colorectal cancer. Oncol Rep 2017; 37: 23–30.
21. Zhang Y, Yang P, Wang X-F. Microenvironmental regulation of cancer metastasis by miRNAs. Trends Cell Biol 2014; 24: 153–60.
22. Nishida N, Nagahara M, Sato T et al. Microarray analysis of colorectal cancer stromal tissue reveals upregulation of two oncoegenic miRNA clusters. Clin Cancer Res 2012; 18: 3054–70.
23. Nielsen BS, Jorgensen S, Fog JG et al. High levels of microRNA-21 in the stroma of colorectal cancers predict short disease-free survival in stage II colon cancer patients. Clin Exp Metastasis 2011; 28: 27–38.
24. Yao Q, Cao S, Li C, Mengesha A, Kong B, Wei M. MicroRNA-21 regulates TGF-beta-induced myofibroblast differentiation by targeting PDLC4 in tumor-stroma interaction. Int J Cancer 2011; 128: 1783–92.
25. Shindo Y, Hazama S, Nakamura Y et al. miR-196b, miR-378a and miR-486 are predictive biomarkers for the efficacy of vaccine treatment in colorectal cancer. Oncol Lett 2017; 14: 1355–62.
26. Uchida N, Tsunoda T, Wada S, Furukawa Y, Nakamura Y, Tahara H. Ring finger protein 43 as a new target for cancer immunotherapy. Clin Cancer Res 2004; 10: 8577–86.
27. Shimosakawa T, Matsushima S, Tsunoda T, Tahara H, Nakamura Y, Furukawa Y. Identification of TOMM34, which shows elevated expression in the majority of human colon cancers, as a novel drug target. Int J Oncol 2006; 29: 381–6.
28. Suda T, Tsunoda T, Daigo Y, Nakamura Y, Tahara H. Identification of human leukocyte antigen-A24-restricted epitope peptides derived from gene products upregulated in lung and esophageal cancers as novel targets for immunotherapy. Cancer Sci 2007; 98: 1803–8.
29. Ishizaki H, Tsunoda T, Wada S, Yamauchi M, Shibuya M, Tahara H. Inhibition of tumor growth with antiangiogenic cancer vaccine using epitope peptides derived from human vascular endothelial growth factor receptor 1. Clin Cancer Res 2004; 10: 8577–86.
Fig. S2. Overall survival (OS) according to miRNA expression and dashed line shows low miRNA expression. Statistical analysis was done using the log-rank test. HLA, human leukocyte antigen; miR, microRNA.

Supporting Information

Additional Supporting Information may be found online in the supporting information tab for this article:

Table S1. Top 30 miRNAs upregulated or downregulated in a responder group compared with a non-responder group, as assessed using microarray analysis.

Table S2. Frequency of severe adverse events (CTCAE version 3.0) in four groups classified according to miR-378a expression and HLA-A status.

Fig. S1. Overall survival (OS) according to number of predictive factors. OS of the HLA-A*2402-matched (left side) and -unmatched groups (right side) of phase II study patients according to the number of predictive factors (high expression of miR-125b-1 and/or miR-378a). (a) Predictive factors in cancer cells. (b) Predictive factors in stromal cells. Dotted line shows the survival curve of patients with 0 factors. Solid line shows the survival curve of patients with one factor and the dashed line shows the survival curve of patients with two factors. Statistical analysis was done using the log–rank test. HLA, human leukocyte antigen.

Fig. S2. Overall survival (OS) according to miRNA expression and HLA-A status. (a) According to miR-125b-1 in cancer cells. (b) According to miR-125b-1 in stromal cells. (c) According to miR-378a in cancer cells. (d) According to miR-378a in stromal cells. Red line shows HLA-A*2402-matched group and black line shows -unmatched group of phase II study patients. Solid line shows high miRNA expression and the dashed line shows low miRNA expression. Statistical analysis was done using the log-rank test. HLA, human leukocyte antigen; miR, microRNA.